Drug Profile
Research programme: staphylococcal infection therapy - Elusys Therapeutics
Alternative Names: ETI-211; Staph aureus HP antibodyLatest Information Update: 22 Apr 2022
Price :
$50
*
At a glance
- Originator Elusys Therapeutics
- Developer Elusys Therapeutics; Pfizer
- Class Antibacterials; Monoclonal antibodies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Methicillin-resistant Staphylococcus aureus infections; Staphylococcal infections
Most Recent Events
- 20 Apr 2022 Elusys Therapeutics has been acquired by Heat Biologics
- 04 Nov 2017 No recent reports of development identified for preclinical development in Methicillin-resistant-Staphylococcus-aureus-infections in USA (Parenteral, Injection)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Staphylococcal-infections in USA (Parenteral, Injection)